Session I: WM I

Moderator(s)

• 

  Jordan Berlin, MD

  Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
  Nashville, Tennessee

Presenter(s)

• 

  Prashant Kapoor, MD

  Mayo Clinic
  Rochester, Minnesota
• 

  Leo Gordon, MD

  Northwestern University Feinberg School of Medicine
  Chicago, Illinois
• 

  Jeffrey Matous, MD

  CBCI- Colorado Blood Cancer Institute
  Denver, Colorado

Presentations:

• 1:00 PM – 1:05 PM

  Welcome and Polling
  

  Chair: Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
• 1:05 PM – 1:25 PM

  The Genomics of Waldenström Macroglobulinemia
  

  Speaker: Prashant Kapoor, MD – Mayo Clinic
• 1:25 PM – 1:45 PM

  Current and Emerging Treatment Options in Waldenström Macroglobulinemia
  

  Speaker: Leo I. Gordon, MD – Northwestern University Feinberg School of Medicine
• 1:45 PM – 1:52 PM

  Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - BR
  

  Speaker: Prashant Kapoor, MD – Mayo Clinic
• 1:52 PM – 1:59 PM

  Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - BTK
  

  Debate Speaker: Jeffrey Matous, MD – CBCI- Colorado Blood Cancer Institute
• 1:59 PM – 2:05 PM

  Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - DISCUSSION
  

  Moderator: Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

  Panelist: Prashant Kapoor, MD – Mayo Clinic

  Panelist: Jeffrey Matous, MD – CBCI- Colorado Blood Cancer Institute
• 2:05 PM – 2:35 PM

  Q&A and Polling
  

  Moderator: Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

  Panelist: Leo I. Gordon, MD – Northwestern University Feinberg School of Medicine

  Panelist: Prashant Kapoor, MD – Mayo Clinic

  Panelist: Jeffrey Matous, MD – CBCI- Colorado Blood Cancer Institute